Equities analysts expect CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to post earnings of ($0.04) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for CASI Pharmaceuticals’ earnings. CASI Pharmaceuticals reported earnings per share of ($0.08) in the same quarter last year, which indicates a positive year over year growth rate of 50%. The company is expected to announce its next earnings report on Monday, August 21st.

According to Zacks, analysts expect that CASI Pharmaceuticals will report full year earnings of ($0.16) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.19) to ($0.16). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow CASI Pharmaceuticals.

CASI Pharmaceuticals (NASDAQ:CASI) last posted its earnings results on Monday, May 15th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01.

Separately, Maxim Group set a $4.00 price target on CASI Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 16th.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/06/13/0-04-earnings-per-share-expected-for-casi-pharmaceuticals-inc-casi-this-quarter.html.

CASI Pharmaceuticals (NASDAQ CASI) traded up 2.9082% during mid-day trading on Tuesday, reaching $1.0085. The company had a trading volume of 331 shares. CASI Pharmaceuticals has a one year low of $0.82 and a one year high of $1.76. The firm’s 50-day moving average is $1.05 and its 200-day moving average is $1.25. The firm’s market capitalization is $60.71 million.

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC boosted its stake in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 103.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 124,800 shares of the biotechnology company’s stock after buying an additional 63,500 shares during the period. Renaissance Technologies LLC owned about 0.21% of CASI Pharmaceuticals worth $144,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.90% of the company’s stock.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Get a free copy of the Zacks research report on CASI Pharmaceuticals (CASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.